Simvastatin downregulates expression of TGF-βRII and inhibits proliferation of A549 cells via ERK
- 233 Downloads
Lung cancer is the leading cause of cancer-related death worldwide. Transforming growth factor-β receptor II (TGF-βRII) plays an important role in the regulation of proliferation and progression in cancer. Statins have been documented to exhibit anticancer and cancer chemopreventive properties. However, the effects and mechanisms of simvastatin on the development of lung cancer are still unclear. In the present study, quiescent A549 cells were treated in vitro with fetal bovine serum (FBS) in the presence or absence of simvastatin. MTT, Western blot, and real-time qPCR were used to detect cell viability, activation of ERK, and expression of TGF-βRII at the protein and RNA level. Our results demonstrated that simvastatin inhibited activation of ERK, downregulated expression of TGF-βRII, and suppressed A549 cell proliferation. Furthermore, the effects of simvastatin can be reversed by farnesyl pyrophosphate (FPP). Therefore, these results suggest that simvastatin may inhibit A549 cell proliferation and downregulate TGF-βRII expression by inhibiting activation of ERK. Our findings may advance the current understanding of the effects of simvastatin on cancer progression and contribute to the study of cancer treatment.
KeywordsTGF-βRII A549 cells Simvastatin ERK
This work was supported by a grant from the National Natural Science Foundation of China (No. 81273957).
Conflicts of interest
- 8.Hsu HY, Lin TY, Wu YC, Tsao SM, Hwang PA, Shih YW, Hsu J: Fucoidan inhibition of lung cancer in vivo and in vitro : Role of the smurf2-dependent ubiquitin proteasome pathway in tgfbeta receptor degradation. Oncotarget 2014Google Scholar
- 18.McAnally JA, Gupta J, Sodhani S, Bravo L, Mo H. Tocotrienols potentiate lovastatin-mediated growth suppression in vitro and in vivo. Exp Biol Med. 2007;232:523–31.Google Scholar
- 19.Hausding M, Witteck A, Rodriguez-Pascual F, von Eichel-Streiber C, Forstermann U, Kleinert H. Inhibition of small g proteins of the rho family by statins or clostridium difficile toxin b enhances cytokine-mediated induction of no synthase ii. Br J Pharmacol. 2000;131:553–61.CrossRefPubMedPubMedCentralGoogle Scholar
- 25.Zhang Z, Sethiel MS, Shen W, Liao S, Zou Y. Hyperoside downregulates the receptor for advanced glycation end products (rage) and promotes proliferation in ecv304 cells via the c-jun n-terminal kinases (jnk) pathway following stimulation by advanced glycation end-products in vitro. Int J Mol Sci. 2013;14:22697–707.CrossRefPubMedPubMedCentralGoogle Scholar
- 30.Bacman D, Merkel S, Croner R, Papadopoulos T, Brueckl W, Dimmler A. Tgf-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower tgf-beta1 expression in colon carcinoma: A retrospective study. BMC Cancer. 2007;7:156.CrossRefPubMedPubMedCentralGoogle Scholar